

Mauricio Tohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1460889/publications.pdf>

Version: 2024-02-01

150
papers

7,391
citations

101384

36
h-index

62479

80
g-index

222
all docs

222
docs citations

222
times ranked

5137
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression. Archives of General Psychiatry, 2003, 60, 1079.	13.8	797
2	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	4.0	579
3	Outcome in Mania. Archives of General Psychiatry, 1990, 47, 1106.	13.8	507
4	The McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence. American Journal of Psychiatry, 2003, 160, 2099-2107.	4.0	412
5	The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disorders, 2009, 11, 453-473.	1.1	401
6	Olanzapine Versus Lithium in the Maintenance Treatment of Bipolar Disorder: A 12-Month, Randomized, Double-Blind, Controlled Clinical Trial. American Journal of Psychiatry, 2005, 162, 1281-1290.	4.0	327
7	Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. British Journal of Psychiatry, 2004, 184, 337-345.	1.7	288
8	Early Intervention in Bipolar Disorder. American Journal of Psychiatry, 2018, 175, 411-426.	4.0	218
9	Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. Bipolar Disorders, 2020, 22, 372-384.	1.1	201
10	A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania. Archives of General Psychiatry, 2003, 60, 1218.	13.8	198
11	Functional impairment and cognition in bipolar disorder. Psychiatric Quarterly, 2000, 71, 309-329.	1.1	187
12	Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disorders, 2011, 13, 87-98.	1.1	155
13	Two-year outcomes in first-episode psychotic depression. Journal of Affective Disorders, 2012, 136, 1-8.	2.0	129
14	Double-Blind Comparison of the Continued Use of Antipsychotic Treatment Versus Its Discontinuation in Remitted Manic Patients. American Journal of Psychiatry, 2004, 161, 169-171.	4.0	125
15	Four-year follow-up of twenty-four first-episode manic patients. Journal of Affective Disorders, 1990, 19, 79-86.	2.0	120
16	Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. British Journal of Psychiatry, 2012, 201, 376-382.	1.7	103
17	What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. Bipolar Disorders, 2019, 21, 394-409.	1.1	98
18	Symptoms and Functioning of Patients With Bipolar Disorder Six Months After Hospitalization. Psychiatric Services, 1988, 39, 652-657.	1.1	89

#	ARTICLE	IF	CITATIONS
19	Results of the COVID-19 mental health international for the general population (COMET-G) study. <i>European Neuropsychopharmacology</i> , 2022, 54, 21-40.	0.3	84
20	Influence of sub-syndromal symptoms after remission from manic or mixed episodes. <i>British Journal of Psychiatry</i> , 2006, 189, 515-519.	1.7	78
21	Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. <i>International Journal of Methods in Psychiatric Research</i> , 2013, 22, 46-58.	1.1	78
22	Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar <sc>CHOICE</sc>). <i>Bipolar Disorders</i> , 2015, 17, 212-223.	1.1	77
23	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 720-740.	1.1	71
24	<p>The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 481-497.	0.7	71
25	Differential Efficacy of Olanzapine and Lithium in Preventing Manic or Mixed Recurrence in Patients With Bipolar I Disorder Based on Number of Previous Manic or Mixed Episodes. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 95-101.	1.1	70
26	The National Comorbidity Survey. , 0, , 343-362.		69
27	Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness). <i>Journal of Clinical Psychiatry</i> , 2016, 77, 90-99.	1.1	69
28	Olanzapine versus lithium in the acute treatment of bipolar mania: A double-blind, randomized, controlled trial. <i>Journal of Affective Disorders</i> , 2008, 105, 101-108.	2.0	62
29	Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar) Tj ETQq1 1 0.784314 rgBT /Overlook 114-127.	0.7	60
30	Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. <i>Bipolar Disorders</i> , 2001, 3, 165-173.	1.1	59
31	Epidemiology of Mood and Anxiety Disorders in Children and Adolescents. , 0, , 657-704.		50
32	Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. <i>Schizophrenia Bulletin</i> , 2015, 41, 1237-1247.	2.3	45
33	Functional outcome assessment in bipolar disorder: A systematic literature review. <i>Bipolar Disorders</i> , 2019, 21, 194-214.	1.1	45
34	Recovery and functional outcomes following olanzapine treatment for bipolar I mania. <i>Bipolar Disorders</i> , 2005, 7, 68-76.	1.1	43
35	Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses. <i>European Neuropsychopharmacology</i> , 2022, 54, 100-115.	0.3	43
36	Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2014, 39, 2549-2559.	2.8	40

#	ARTICLE	IF	CITATIONS
37	Acute risk factors for suicide attempts and death: prospective findings from the STEP-BD study. <i>Bipolar Disorders</i> , 2016, 18, 363-372.	1.1	40
38	The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 230-256.	1.0	38
39	Unipolar Mania Reconsidered: Evidence from an Elderly Cohort. <i>British Journal of Psychiatry</i> , 1994, 164, 547-549.	1.7	37
40	Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. <i>Journal of Affective Disorders</i> , 2014, 164, 57-62.	2.0	37
41	Harnessing the potential of community-based participatory research approaches in bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2016, 4, 4.	0.8	33
42	Predicting Diagnostic Change Among Patients Diagnosed With First-Episode DSM-IV-TR Major Depressive Disorder With Psychotic Features. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 723-731.	1.1	33
43	Epidemiology of Bipolar Disorder. , 0, , 427-444.		31
44	Onset of action of antipsychotics in the treatment of mania. <i>Bipolar Disorders</i> , 2000, 2, 261-268.	1.1	29
45	Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort. <i>Bipolar Disorders</i> , 2016, 18, 247-260.	1.1	29
46	Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5. <i>Journal of Affective Disorders</i> , 2014, 168, 136-141.	2.0	28
47	Epidemiology of Drug Dependence. , 0, , 479-561.		27
48	Increased Activity or Energy as a Primary Criterion for the Diagnosis of Bipolar Mania in DSM-5: Findings From the STEP-BD Study. <i>American Journal of Psychiatry</i> , 2017, 174, 70-76.	4.0	27
49	Long-term treatment of bipolar disorder type I: A systematic and critical review of clinical guidelines with derived practice algorithms. <i>Bipolar Disorders</i> , 2021, 23, 324-340.	1.1	27
50	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. <i>Bipolar Disorders</i> , 2021, 23, 659-678.	1.1	27
51	Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. <i>Journal of Affective Disorders</i> , 2019, 257, 17-22.	2.0	26
52	Symptom Scales and Diagnostic Schedules in Adult Psychiatry. , 0, , 273-332.		25
53	Cultural influences on suicide in Japan. <i>Psychiatry and Clinical Neurosciences</i> , 2017, 71, 2-5.	1.0	24
54	A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. <i>Journal of Affective Disorders</i> , 2016, 192, 212-218.	2.0	22

#	ARTICLE	IF	CITATIONS
55	White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 355-365.	1.3	22
56	Psychotherapy use in bipolar disorder: Association with functioning and illness severity. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 453-461.	1.3	21
57	<i>Epidemiology of Depressive and Anxiety Disorders.</i> , 0, , 389-426.		20
58	Systemic challenges in bipolar disorder management: A patient-centered approach. <i>Bipolar Disorders</i> , 2017, 19, 676-688.	1.1	19
59	Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the Bipolar CHOICE trial. <i>Journal of Affective Disorders</i> , 2014, 161, 30-35.	2.0	18
60	Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 1485-1496.	2.8	18
61	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2017, 223, 146-152.	2.0	18
62	Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial. <i>Journal of Affective Disorders</i> , 2018, 225, 563-568.	2.0	18
63	Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder. <i>Psychoneuroendocrinology</i> , 2020, 112, 104511.	1.3	17
64	<i>The Epidemiology of Child and Adolescent Mental Disorders.</i> , 0, , 629-655.		16
65	The McLean-Harvard First-Episode Project. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 781-788.	1.1	15
66	Clinical Trials in Bipolar Mania. <i>Archives of General Psychiatry</i> , 2008, 65, 252.	13.8	14
67	The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial. <i>Current Medical Research and Opinion</i> , 2021, 37, 1635-1643.	0.9	14
68	Aggression among 216 patients with a first-psychotic episode of bipolar I disorder. <i>International Journal of Bipolar Disorders</i> , 2018, 6, 18.	0.8	13
69	Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. <i>Journal of Affective Disorders</i> , 2019, 259, 164-172.	2.0	13
70	The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study. <i>Journal of Affective Disorders</i> , 2020, 266, 772-781.	2.0	13
71	<i>Methods in Psychiatric Genetics.</i> , 0, , 65-130.		12
72	Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. <i>Depression and Anxiety</i> , 2017, 34, 281-290.	2.0	12

#	ARTICLE	IF	CITATIONS
73	Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	12
74	Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. <i>Journal of Affective Disorders</i> , 2019, 246, 126-131.	2.0	11
75	Epidemiology of Psychosis with Special Reference to Schizophrenia. , 0, , 363-387.		10
76	Analysis of bipolar maintenance treatment with lithium versus olanzapine utilizing Multi-estate Outcome Analysis of Treatments (<scp>MOAT</scp>). <i>Bipolar Disorders</i> , 2016, 18, 282-287.	1.1	10
77	Bipolar mixed features “ Results from the comparative effectiveness for bipolar disorder (Bipolar) Tj ETQq1 1 0.784314 rgBT /Overlo	2.0	10
78	Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2018, 30, 297-305.	1.0	10
79	Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies. <i>International Clinical Psychopharmacology</i> , 2021, 36, 76-83.	0.9	10
80	Introduction to Epidemiologic Research Methods. , 0, , 1-33.		9
81	Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 615-627.	2.2	9
82	Comparison of 71 bipolar disorder pharmacotherapies for kidney disorder risk: The potential hazards of polypharmacy. <i>Journal of Affective Disorders</i> , 2019, 252, 201-211.	2.0	8
83	Glutamatergic hypo-function in the left superior and middle temporal gyri in early schizophrenia: a data-driven three-dimensional proton spectroscopic imaging study. <i>Neuropsychopharmacology</i> , 2020, 45, 1851-1859.	2.8	8
84	Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar I Disorder in Adults: An Evidence-Based Review of Recent Data. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2005-2012.	2.0	8
85	Increased Glutamate Plus Glutamine in the Right Middle Cingulate in Early Schizophrenia but Not in Bipolar Psychosis: A Whole Brain 1H-MRS Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 660850.	1.3	8
86	Preferences of Information Dissemination on Treatment for Bipolar Disorder: Patient-Centered Focus Group Study. <i>JMIR Mental Health</i> , 2019, 6, e12848.	1.7	8
87	Conflicts of interest and the credibility of psychiatric research. <i>World Psychiatry</i> , 2007, 6, 33-4.	4.8	8
88	Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study. <i>Journal of Affective Disorders</i> , 2016, 205, 159-164.	2.0	7
89	Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. <i>Journal of Affective Disorders</i> , 2020, 273, 131-137.	2.0	7
90	Psychiatric collaborations in the Hispanic world. <i>Revista De Psiquiatrãa Y Salud Mental</i> , 2014, 7, 155-156.	1.0	6

#	ARTICLE	IF	CITATIONS
91	Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders. <i>Bipolar Disorders</i> , 2018, 20, 761-771.	1.1	6
92	Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1158-e1166.	1.1	6
93	Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response. <i>Journal of Affective Disorders</i> , 2022, 300, 41-49.	2.0	6
94	The Epidemiology of First-Onset Mania. , 0, , 445-458.		5
95	Analysis of Categorized Data: Use of the Odds Ratio as a Measure of Association. , 0, , 35-63.		5
96	Validity: Definitions and Applications to Psychiatric Research. , 0, , 149-163.		5
97	Treatment Guidelines in Bipolar Disorders and the Importance of Proper Clinical Trial Design. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 95-97.	1.0	5
98	Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 21, 350-360.	1.1	5
99	Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome. <i>Journal of Psychiatric Research</i> , 2021, 140, 205-213.	1.5	5
100	Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder. <i>primary care companion for CNS disorders, The</i> , 2017, 19, .	0.2	5
101	Birth and Development of Psychiatric Interviews. , 0, , 257-271.		4
102	DSM-IV and Psychiatric Epidemiology. , 0, , 333-342.		4
103	The Primacy of Mania. , 2006, , 169-192.		4
104	Carbamazepine, Other Anticonvulsants and Augmenting Agents. , 2006, , 63-83.		4
105	Complex Combination Therapy: The Evolution Toward Rational Polypharmacy in Lithium-Resistant Bipolar Illness. , 2006, , 135-167.		4
106	Collaborations between academic psychiatry and the pharmaceutical industry: A perspective from industry. <i>Epidemiologia E Psichiatria Sociale</i> , 2007, 16, 197-198.	1.0	4
107	Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature Review. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 515-531.	1.0	4
108	Characteristics of Hispanics Referred to Coordinated Specialty Care for First-Episode Psychosis and Factors Associated With Enrollment. <i>Psychiatric Services</i> , 2021, 72, 1407-1414.	1.1	4

#	ARTICLE	IF	CITATIONS
109	Prodromal features in first-psychotic episodes of major affective and schizoaffective disorders. <i>Journal of Affective Disorders</i> , 2021, 295, 1251-1258.	2.0	4
110	Preparation for the Certification Examination*. <i>Canadian Journal of Psychiatry</i> , 1983, 28, 471-474.	0.9	3
111	The significance of mania in old age. <i>Reviews in Clinical Gerontology</i> , 1992, 2, 39-43.	0.5	3
112	Studying the Natural History of Psychopathology. , 0, , 213-238.		3
113	The Epidemiology of Alcohol Use, Abuse, and Dependence. , 0, , 459-477.		3
114	Bipolarity in Women: Therapeutic Issues. , 2006, , 235-277.		3
115	Credibility of industry-funded clinical trials. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1879-1884.	1.0	3
116	Use of Electroconvulsive Therapy in Bipolar Depression. <i>American Journal of Psychiatry</i> , 2015, 172, 3-5.	4.0	3
117	Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 994-1002.	1.3	3
118	Using Machine Learning Imputed Outcomes to Assess Drug-Dependent Risk of Self-Harm in Patients with Bipolar Disorder: A Comparative Effectiveness Study. <i>JMIR Mental Health</i> , 2021, 8, e24522.	1.7	3
119	Mental Health Services Research. , 0, , 165-179.		2
120	The Developmental Epidemiology of Psychiatric Disorders. , 0, , 239-255.		2
121	The Pharmacoepidemiology of Psychiatric Medications. , 0, , 181-194.		2
122	Personality Disorders: Epidemiological Findings, Methods, and Concepts. , 0, , 563-599.		2
123	Epidemiology and Geriatric Psychiatry. , 0, , 601-628.		2
124	The Pivotal Role of Psychoeducation in the Long-Term Treatment of Bipolar Disorder. , 2006, , 333-345.		2
125	Haloperidol and Risperidone in Mania. , 2006, , 105-123.		2
126	Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials. <i>Acta Neuropsychiatrica</i> , 2019, 31, 230-234.	1.0	2

#	ARTICLE	IF	CITATIONS
127	Chronbiologically-based sub-groups in bipolar I disorder: A latent profile analysis. <i>Journal of Affective Disorders</i> , 2022, 299, 691-697.	2.0	2
128	The Scope of Bipolar Disorders. , 2006, , 1-8.		1
129	Psychosocial Interventions in Bipolar Disorders: Rationale and Effectiveness. , 2006, , 313-332.		1
130	The Role of Treatment Setting in the Pharmacotherapy of Bipolar Disorder. , 2006, , 347-352.		1
131	Suicide Prevention. , 2006, , 353-365.		1
132	A Comparison of "Second Generation Antipsychotics" in the Treatment for Bipolar Disorder: Focus on Clozapine, Quetiapine, Ziprasidone and Aripiprazole. , 2006, , 125-134.		1
133	Valproate: Clinical Pharmacological Profile. , 2006, , 27-42.		1
134	Psychiatric collaborations in the Hispanic world. <i>Revista De Psiquiatría Y Salud Mental (English)</i> Tj ETQq0 0 0 rgBT (Overlock 10 Tf 50 46	0.2	1
135	The need to change from a phenomenological to a target engagement approach. <i>Bipolar Disorders</i> , 2017, 19, 513-514.	1.1	1
136	Long-term morbidity in major affective and schizoaffective disorders following hospitalization in first psychotic episodes. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 50-60.	2.2	1
137	Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. <i>Psychiatry Research</i> , 2021, 305, 114194.	1.7	1
138	Peering into the Future of Psychiatric Epidemiology. , 0, , 195-211.		0
139	Diagnostic and Clinical Management Approaches to Bipolar Depression, Bipolar II and Their Comorbidities. , 2006, , 193-234.		0
140	Treatment for Bipolar Disorder in Older Adults. , 2006, , 301-311.		0
141	Pediatric Bipolar Disorder: The Promise of Psychopharmacotherapy. , 2006, , 279-299.		0
142	Principles of Caring for Bipolar Patients. , 2006, , 367-387.		0
143	Lithium Treatment: Focus on Long-Term Prophylaxis. , 2006, , 9-26.		0
144	Pharmacological Profile and Clinical Utility of Lamotrigine in Bipolar Disorders. , 2006, , 43-62.		0

#	ARTICLE	IF	CITATIONS
145	Olanzapine in Treatment for Bipolar Disorder. , 2006, , 85-103.		0
146	Olanzapine as Maintenance Therapy in Patients with Bipolar I Disorder. Progress in Neurotherapeutics and Neuropsychopharmacology, 2007, 2, 225-238.	0.0	0
147	In Memoriam - Vivek Singh. Journal of Affective Disorders, 2016, 193, 144.	2.0	0
148	Severity of symptoms in maniaâ€”clinical guidelines and study design implications. Bipolar Disorders, 2018, 20, 171-172.	1.1	0
149	Psychiatric Epidemiology. , 0, , 401-432.		0
150	Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder. Psychopharmacology Bulletin, 2021, 51, 8-19.	0.0	0